---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-26-000013"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2026-08-11T20:07:48+00:00"
generated_at: "2026-08-11T20:09:23.406001+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# SELLAS Q2 2026 net loss $9.6M; GPS Phase 3 nears 80th-event final analysis

## Summary
- Q2 2026 net loss $9.6M ($0.05/sh) vs $6.6M ($0.07/sh) in Q2 2025; H1 loss $18.0M.
- R&D expense $6.3M in Q2 2026 (vs $3.9M) on BLA prep for GPS; G&A $4.4M (vs $3.0M).
- Cash and equivalents $138.3M as of June 30, 2026.
- Phase 3 REGAL (GPS) in AML will conduct final analysis after pre-specified 80th event; timing unannounced.
- 28 patients enrolled in Phase 2 SLS009 frontline AML; topline data expected Q4 2026; preclinical PDAC data upcoming.

## SEC filing metadata
- accession: 0001390478-26-000013
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2026-08-11T20:07:48+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/0001390478-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-26-000013
- JSON: https://secwatch.observer/filing/0001390478-26-000013.json
- Plain text: https://secwatch.observer/filing/0001390478-26-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.